Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.46 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24666420 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MAPTCYP3A4MEN1CYP1A2 | |
| SCHEMBL13175755 | 0.85 | HTR4 (0.44) | ALDH1A1MAPTCYP3A4MEN1CYP1A2 | |
| SCHEMBL6998810 | 0.85 | HTR4 (0.47) | ALDH1A1MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14452333 | 0.85 | RAB9A (0.50) | ALDH1A1MAPTCYP3A4MEN1CYP1A2 | |
| SCHEMBL23224211 | 0.85 | IMPDH2 (0.60) | ALDH1A1MAPTCYP3A4MEN1CYP1A2 | |
| SCHEMBL6997419 | 0.83 | TAS1R3 (0.52) | ALDH1A1MAPTCYP3A4MEN1CYP1A2 | |
| SCHEMBL72600 | 0.82 | PLK1 (0.53) | ALDH1A1MAPTCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL9473662 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MAPTCYP3A4MEN1CYP1A2 | |
| SCHEMBL5678411 | 0.82 | CA1 (0.56) | ALDH1A1MAPTCYP3A4MEN1CYP1A2 | |
| SCHEMBL2952897 | 0.82 | MAPT (0.48) | ALDH1A1MAPTKMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
| EP-0950047-B1 | INDOLIN-2-ONE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI SYNTHELABO (FR) | 2003-10-15 | — | — | EP | disclosed |
| EP-0873309-B1 | 3-SPIRO-INDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | SANOFI SYNTHELABO (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-6090818-A | CARDIOVASCULAR DISORDERS; ANTISECRETORY AGENTS; OXYTOCIN, VASOPRESSIN ANTAGONIST | SANOFI-SYNTHELABO (FR) | 2000-07-18 | — | — | US | disclosed |
| US-6046341-A | AN ACTIVE DRUG HAVING AFFINITY FOR VASOPRESSIN AND/OR OXYTOCIN RECEPTORS | SANOFI-SYNTHELABO (FR) | 2000-04-04 | — | — | US | disclosed |
| US-5994350-A | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS; RESPIRATORY SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 1999-11-30 | — | — | US | disclosed |
| EP-0950047-A1 | INDOLIN-2-ONE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 1999-10-20 | — | — | EP | disclosed |
| EP-0873309-A1 | 3-SPIRO-INDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | SANOFI (FR) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998025901-A1 | INDOLIN-2-ONE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1998-06-18 | — | — | WO | disclosed |
| WO-1997015556-A1 | 3-SPIRO-INDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | SANOFI (FR) | 1997-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ALDH1A1 4333/4885MAPT 470/4885CYP3A4 4198/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ALDH1A1 3674/4885MAPT 501/4885CYP3A4 3280/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ALDH1A1 4333/4885MAPT 470/4885CYP3A4 4198/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | ALDH1A1 4184/4885MAPT 438/4885CYP3A4 4148/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | ALDH1A1 4184/4885MAPT 438/4885CYP3A4 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.